Chandan Healthcare Ltd (CHANDAN) Q1FY27 Concall Summary - Jun-2026 Qtr
Performance Overview
- The company reported healthy growth across key financial and operating parameters, driven by the continued expansion of its diagnostic network and steady progress in partnership-led initiatives.
- A significant strategic move was the divestment of the entire 53.56% stake in Chandan Pharmacy Limited for approximately INR 16.7 crores, allowing the company to sharpen its focus on the higher-margin core diagnostics business.
- The company demonstrated aggressive network expansion, adding 134 franchise centers, 1 comprehensive diagnostic center, 2 diagnostic centers, and 3 standalone labs during the quarter, bringing the total network to 327 centers.
- Strong, broad-based growth was observed across all business verticals, with B2B growing 94% YoY, B2G by 22% YoY, and B2C by 20% YoY, reflecting the increasing scale and reach of the company's network.
- The management has set an ambitious target to scale its franchise network to 1,000 centers within the current financial year and 3,000 centers in the next two years, a significant acceleration from the previous goal of 1,000 centers in three years.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.